Skip to content
OpenCapital
Get started

Inhibikase Therapeutics, Inc. IKT Q4 2024 Annual earnings

Reported March 26, 2025 · Before market open

Diluted EPS-$0.63Miss by $0.53
EPS estimate-$0.10

Next report

Aug 13, 2026 (in a month)
EPS estimate-$0.09

Versus estimates

Diluted EPS

Q1 2026-$0.10In lineQ4 2025-$0.09Beat by $0.03Q3 2025-$0.13In lineQ2 2025-$0.11Miss by $0.02Q1 2025-$0.15Miss by $0.04
Q4 2024-$0.63Miss by $0.53

Ask the moment Inhibikase Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Inhibikase Therapeutics, Inc. report Q4 2024 earnings?
Inhibikase Therapeutics, Inc. (IKT) reported Q4 2024 earnings on March 26, 2025 before market open.
What were Inhibikase Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Inhibikase Therapeutics, Inc. reported diluted EPS of $-0.63 for Q4 2024.
Did Inhibikase Therapeutics, Inc. beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.10 by $0.53.
Where can I find Inhibikase Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-046096) directly on SEC EDGAR. The filing index links above go to sec.gov.